Physical activity levels of FH patients/Cardiovascular Risk Factors
Research type
Research Study
Full title
The impact of a physical activity intervention in patients with familial hypercholesterolaemia to reduce cardiovascular disease risk factors
IRAS ID
368511
Contact name
Jillian Webster
Contact email
Sponsor organisation
York Teaching Hospitals
Duration of Study in the UK
0 years, 6 months, 0 days
Research summary
Familial Hypercholesterolaemia (FH) is an inherited condition which leads to exceptionally high cholesterol levels,
often double and occasionally, four times those of the general population (BHF, 2018). One in 250 of the general
population has FH but many are as yet undiagnosed, leaving individuals at high risk of developing cardiovascular
disease and dying suddenly at a premature age from a heart attack. On average, the untreated condition shortens life
expectancy by 20-30 years, although early treatment through statins is likely to be effective in preventing cardiovascular
disease. However, this presents a financial implication through pharmacological interventions. Whereas, lifestyle
modifications (such as physical activity (PA), smoking cessation and alcohol reduction to recommended limits), dietary
management and careful monitoring can allow people with FH to achieve the same life expectancy as those without
the conditionIdentifying what impact PA, and potential mechanisms, by which PA could reduce cardiovascular disease
within the FH and non-FH populations is a vital part of the management of this genetic condition. There are currently
no targeted regimes for the FH population and this research would complement the provision of precision lifestyle and
dietary advice to this group of people, enhancing the existing service and supplement current pharmaceutical
therapies.FH elevates low-density lipoprotein cholesterol (LDL-C) and increases cardiovascular disease (CVD) risk. The aim of the study will be to identify in those with FH what effect, if any, physical activity has upon their LDL-C levels and provide an idea of the preliminary effect of PA upon CVD outcomes relating to lowering LDL-C levels by utilising an intervention designed to improve PA in individuals with FH.REC name
North West - Preston Research Ethics Committee
REC reference
26/NW/0087
Date of REC Opinion
2 Apr 2026
REC opinion
Unfavourable Opinion